Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M

MYRIAD GENETICS INC

2025-FY EPS reported -$3.95 revenue$824,500,000

Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.
Full year 2025 test volumes ~1.5M (+1% YoY): hereditary cancer +7%, mental health +6%, prenatal -4%.
FY 2026 revenue guidance $860-880M (midpoint +6% vs FY25 prelim midpoint).
FY 2026 adjusted gross margin guidance 68-69%; adjusted EBITDA $37-49M (midpoint +43% vs prior FY25 guide).
Formal Q4/FY 2025 earnings call scheduled for February 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.